Lupus patients continue to show interest in experimental CAR-T cell therapy despite four deaths reported in clinical trials involving treatments for autoimmune diseases. Doctors say many patients with severe lupus are willing to consider the risks in the hope of achieving long-term remission. The four deaths were linked to clinical trials involving Novartis and Bristol Myers Squibb. Three patients died in trials associated with Novartis, while one death was reported in a Bristol Myers Squibb trial. Both companies have paused their respective autoimmune disease programmes while safety investigations continue. CAR-T therapy involves modifying a patient's immune cells to recognise and attack specific targets before returning them to the body. Although the treatment has been used successfully for certain blood cancers, researchers are investigating its potential to treat difficult autoimmune conditions. Early research has raised hopes among lupus specialists. A 2022 study involving five lupus patients reported remission following CAR-T treatment. Subsequent studies have also indicated the possibility of sustained remission in some patients. However, serious safety concerns remain. Novartis reported three deaths associated with a rare inflammatory complication known as immune effector cell-associated haemophagocytic syndrome (IEC-HS). Researchers are examining whether rapid cell-manufacturing methods could contribute to severe inflammatory reactions. The exact circumstances surrounding all four deaths have not been fully disclosed. Despite these concerns, doctors say patients continue to enquire about clinical trial participation. With existing treatments, including steroids, immunosuppressants and targeted biologics, sometimes failing to control the disease, experimental therapies continue to attract interest. According to the report, around 10% to 15% of people with lupus die prematurely, highlighting the urgent need for more effective treatment options.
CAR-T Trial Deaths Fail to Deter Lupus Patients Seeking a Cure
Despite four reported deaths in clinical trials involving experimental CAR-T therapies for autoimmune diseases, lupus patients continue to seek the treatment. Many hope it could offer relief from a debilitating condition that existing medicines often fail to control.


0 comments
No comments yet. Yours would be the first.